Sinovac Schedules Investor Conference Call for February 6, 2007
Friday February 2, 9:00 am ET
BEIJING, Feb. 2 /PRNewswire-FirstCall/ -- Sinovac Biotech Ltd. (Amex:
SVA -
News), a leading provider of biopharmaceutical products in China, today announced that it has scheduled an investor conference call at 12:30 pm ET on Tuesday, February 6, 2007. Ms. Nan Wang, Vice General Manager, and Helen Yang, International Finance Manager, will review Sinovac's corporate presentation.
The corporate presentation and a live Web cast of the conference call will be available online on the IR Home page of the Investors section of Company's corporate Web site at
www.sinovac.com.
The dial-in numbers are (877) 407-4018 for domestic callers, and (201) 689-8471 for international. After the live Web cast, the call will remain available on Sinovac's web site until February 13, 2007. In addition, a telephonic replay of the call will be available until February 13, 2007. The replay dial-in numbers are (877) 660-6853 for domestic callers and (201) 612- 7415 for international callers. Please use account number 3055 and conference ID number 230156.
About Sinovac
Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac's vaccines include Healive(TM) (hepatitis A), Bilive(TM) (combined hepatitis A and B) and Anflu(TM) (influenza). Sinovac is currently developing human vaccines against the H5N1 strain of pandemic influenza, Japanese encephalitis and SARS. Additional information about Sinovac is available on its website,
http://www.sinovac.com. To be added to our distribution list, please email:
info@sinovac.com.
Safe Harbor Statement
This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the business outlook and quotations from management in this press release contain forward-looking statements. Statements that are not historical facts, including statements about Sinovac's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward- looking statement. Sinovac does not undertake any obligation to update any forward-looking statement, except as required under applicable law.
Contact Information: Investors/Media:
Helen G. Yang Stephanie Carrington/Janine McCargo
Sinovac Biotech Ltd. The Ruth Group
Phone: +86-10-82890088 Ext. 871 (646) 536-7017/7033
About SINOVAC
Sinovac Biotech Ltd. (SINOVAC) is a China-based global biopharmaceutical company, with a mission of "supply vaccines to eliminate human diseases", the company specializes in the research, development, manufacturing and commercialization of vaccines and related biological products that protect against human infectious diseases.
The company's diversified portfolio includes vaccines for influenza, viral hepatitis, varicella, Hand-Foot-Mouth disease (HFMD), poliomyelitis, pneumococcal disease, etc., of which 3 vaccines have been prequalified by WHO, including inactivated hepatitis A vaccine Healive®, Sabin-strain inactivated polio vaccine (sIPV), and varicella vaccine.
SINOVAC has a leading edge in developing vaccines to combat infectious disease outbreaks and was among the first to initiate R&D during major public health emergencies, including SARS, H5N1, H1N1, and COVID-19. The company developed the world's first inactivated SARS vaccine (Phase I completed), China's first H5N1 influenza vaccine (Paneflu®), the world's first H1N1 influenza vaccine (Panflu.1®), and CoronaVac®, the most widely used inactivated COVID-19 vaccine globally.
Beyond its marketed portfolio, the company is advancing a robust pipeline that includes combination vaccines,recombinant protein vaccines and next-generation platforms such as mRNA technologies and antibodies.
With a long-standing commitment to innovation and global health, SINOVAC is expanding its global footprint by strengthening partnerships with research institutions, international organizations, and local partners. Through broader market presence, technological cooperation, and localized production, the company aims to accelerate vaccine development and supply, enhance regional access to high-quality products, and better address unmet medical needs while improving preparedness for future pandemics.
For more information, please see the Company’s website at www.sinovac.com.
EN
